LYON, France, Nov 26, 2008 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it showcased the Ablatherm-HIFU technology and next generation Sonolith I-Sys device at the French Association of Urology (AFU) Annual Meeting from November 19-22, 2008 in Paris, France.

During the meeting, EDAP educated urologists about Ablatherm-HIFU's minimally invasive approach for the treatment of localized prostate cancer. Urologists with various levels of Ablatherm experience assessed HIFU's robotized approach while sharing peer-to-peer experiences highlighting the technology's proven track record. EDAP also detailed the purpose of its @-Registry program ("Ablatherm Treatment"- Registry), a centralized comprehensive database of follow-up results from patients treated with Ablatherm-HIFU, which facilitated discussions and widened physician registration in support of continued HIFU adoption.

During this gathering of Ablatherm users organized by the HIFU Club, EDAP launched its "Ultrasonic Therapy Community" (U&T Community), a novel interactive web marketing tool representing the Company's commitment to educating physicians about HIFU and Lithotripsy. This U&T Community is a feature registered link on EDAP's website that provides physicians with comprehensive information and recruitment materials, and serves as an open community for Ablatherm-HIFU and Lithotripsy users to discuss their experiences peer-to-peer while generating awareness of the benefits afforded by these technologies.

Pierre Reboul, French Business Unit Director, commented, "We are very pleased with the strong attendance at EDAP's booth and the increasing number of contact leads we recorded in the four days at the AFU Meeting. Interest and enthusiasm for our technologies is growing among urologists, stemming from both public hospitals and private clinics eager to integrate HIFU into the therapeutic solutions offered to their patients with prostate cancer."

Marc Oczachowski, EDAP's Chief Executive Officer, added, "We are extremely pleased by the success of this meeting. French urologists, through AFU association, reiterated their confidence in Ablatherm-HIFU technology and its positive outcomes in the treatment of localized prostate cancer. This support is in line with the AFU's recent recommendation of HIFU as a positive and proven therapeutic solution for patients with prostate cancer. AFU has been actively and closely working with French authorities supporting HIFU reimbursement. We are very appreciative of the reference made to Ablatherm-HIFU during an official press conference organized by AFU where urologists quoted our technology as an example case that urgently needs official reimbursement recognition, despite a lack of visibility in the timing of reimbursement outcomes."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com or http://www.urotoday.com/HIFU.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS S.A.

EDAP TMS SA
         Blandine Confort, Investor Relations / Legal Affairs
         +33 4 72 15 31 72
         bconfort@edap-tms.com
         
         The Ruth Group
         Investors:
         R.J. Pellegrino
         646-536-7009
         rpellegrino@theruthgroup.com

(C) Copyright 2008 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX